Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Cool, I'll take a look. I was wondering if he was going to be providing Caverstem, lol.
I would assume that .088 pps would be very enticing in the future if the stock grows as one would expect with successful commercialization of one or multiple treatments. I'd also assume they were provided current revenue, projected revenue, and discussed the CMTH business plan in depth. Taking that into account, the possible profit on shares around .10 cents compared to where it would be in a few years would seem to be a pretty enticing proposition. I'd also assume that would mean they investment organizations, having reviewed that information, would likewise agree, which would be why they would agree to terms.
FemCelz.com
@CaverStem sister treatment for #femalesexualdysfunction #FemCelz had a domain registered by CMTH back on 9/12.
http://www.creativemedicaltechnology.com/female-sexual-dysfunction/
#stemcells #WomensHealth @NBCNewsHealth @cnnhealth @HarvardHealth @WomensHealthMag
I'd say almost all of it is derived from postings on their social media and/or PR's. The only things that aren't, are specific dates for when domains/websites become active. Everything else is from the source, and even some of the website things are corroborated by their PR's. For instance, when I posted that the LA website was active for Dr. Gershman, I stipulated that probably meant they were going to update their "Find a Doctor" page on the main Caverstem page with all the providers, as it had previously just been Dr. Gershman's info. They did end up doing that exact thing, and then in the PR, they mentioned that going forward they would be putting all new doctors info on that page.
Updated DD list since AUA Conference with links to source/b] Alexander Gershman, M.D. is a Board-Certified Urologist & is considered to be one of the world’s leading Urology experts in the area of minimally invasive surgery. https://t.co/AzauL896wZ #urology #ErectileDysfunction #caverstem #ed #beverlyhills #maleenhancement pic.twitter.com/HGdTrTLcOT Dr. Alexander Gershman performing the first part of the #CaverStem Procedure which is Bone Aspiration. #StemCells #ErectileDysfunction #LosAngeles pic.twitter.com/yYznwViH5L CaverStem International - Switzerland pic.twitter.com/lA61DjBmHS
May 20 - Introducing Caverstem at AUA Conference in San Francisco - http://www.caverstem.com/creative-medical-technology-holdings-inc-to-unveil-its-patented-caverstem-procedure-for-erectile-dysfunction-at-international-urology-conference/
May 21 - 10-Q published - http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=12269334&type=HTML&symbol=CELZ&companyName=Creative+Medical+Technology+Holdings+Inc&formType=10-Q&dateFiled=2018-05-21
May 22 - Social media campaign begins(Hired someone for outreach and Dr. Gershman’s social media accounts created) -
May 23 - PR on AUA Conference - https://www.prnewswire.com/news-releases/caverstem-adult-stem-cell-therapy-for-erectile-dysfunction-receives-positive-reception-at-international-urology-conference-300653752.html
May 30 - Announced VP of Sales - https://www.prnewswire.com/news-releases/shareholder-update-award-winning-sales-executive-to-join-company-as-vice-president-of-sales-300656514.html
May 30 - Registered 12 new clinic location websites - https://twitter.com/JBizzle703/status/1004883467052691457
June 7 - 8K, Dr. Timothy Henry joins Advisory Board, recap of AUA - http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=12301202&type=HTML&symbol=CELZ&companyName=Creative+Medical+Technology+Holdings+Inc&formType=8-K&dateFiled=2018-06-07
June 8 - Registered 5 more clinical location websites - https://twitter.com/JBizzle703/status/1006355790419185665
June 16 - Registered 10 more clinical location websites - https://twitter.com/JBizzle703/status/1010914006620614658
June 17 - StemSpine Facebook page created - https://www.facebook.com/StemSpine-1715913745191312/
June 18 - Videos of Caverstem Procedures put out by Dr. Gershman -
Urology Updates Facebook page created - https://www.facebook.com/Urology-Updates-257851814950618/
June 19 - PR on formation of Caverstem International - https://www.sec.gov/Archives/edgar/data/1187953/000114420418035154/tv496960_ex99-1.htm
June 21 - 8K on Caverstem International - http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=12322977&type=HTML&symbol=CELZ&companyName=Creative+Medical+Technology+Holdings+Inc&formType=8-K&dateFiled=2018-06-21
June 23 - Registered 5 more clinical location websites - https://twitter.com/JBizzle703/status/1011396887356825600
June 26 - New Gershman videos discussing Caverstem, Caverstem Youtube Channel launched - https://www.facebook.com/caverstem/videos/2459634247383796/ https://www.youtube.com/channel/UCqXes01LJZdZUYZoGVSoHDw
June 27 - Caverstem-NM website became active - https://twitter.com/JBizzle703/status/1012117135055900672
July 6 - PR AmnioStem treatment of Cachexia/Right to Try Law - https://www.prnewswire.com/news-releases/creative-medical-technology-holdings-aims-to-treat-cancer-associated-wasting-cachexia-using-amniostem-universal-donor-stem-cell-300676909.html
July 9 - Caverstem AUA Conference Video - https://www.facebook.com/InstituteforAdvancedUrology/videos/278486582708707/
July 12 - 8K, recap of AmnioStem PR - http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=12353536&type=HTML&symbol=CELZ&companyName=Creative+Medical+Technology+Holdings+Inc&formType=8-K&dateFiled=2018-07-12
July 16 - Mentioned in Politico article - https://www.politico.com/newsletters/prescription-pulse/2018/07/16/comments-roll-in-on-trumps-drug-pricing-plan-279843
July 17 - Caverstem-Sanfrancisco website became active - https://twitter.com/JBizzle703/status/1019347212101447681
July 19 - PR announcing exclusive contract with Promo Med Russia - https://finance.yahoo.com/news/creative-medical-technology-holdings-announces-121500249.html
July 20 - 7 new Caverstem video ads released - https://www.youtube.com/channel/UCqXes01LJZdZUYZoGVSoHDw
July 24 - 8K, recap of Russian contract with Promo Med Russia - http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=12367044&type=HTML&symbol=CELZ&companyName=Creative+Medical+Technology+Holdings+Inc&formType=8-K&dateFiled=2018-07-24
Dr. Victor Liu information provided on San Francisco Caverstem page - http://www.caverstem-sanfrancisco.com/dr-victor-liu/
August 1 - Caverstem-San Diego website became active - https://twitter.com/JBizzle703/status/1024714409162276875
Dr. Scott L. Brown information added to San Diego website - http://www.caverstem-sandiego.com/dr-scott-l-brown/
August 10 - Registered 8 more international location websites - https://twitter.com/JBizzle703/status/1028984462418345986
August 12 - Caverstem International Facebook Page Created - https://www.facebook.com/CaverStem-International-210566523142371/
August 13 - Caverstem announced signing of Alta Uro/Dr. Buchmann in Switzerland - https://www.facebook.com/caverstem/
August 14 - 10-Q release on time - http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=12411265&type=HTML&symbol=CELZ&companyName=Creative+Medical+Technology+Holdings+Inc&formType=10-Q&dateFiled=2018-08-14
8-K released on new promissory note, not convertible into equity(cash payment only) - http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=12411229&type=HTML&symbol=CELZ&companyName=Creative+Medical+Technology+Holdings+Inc&formType=8-K&dateFiled=2018-08-14
PR released on Caverstem doctors signups, international news, debt reduction, Caverstem trial, and future treatments - https://finance.yahoo.com/news/shareholder-creative-medical-technology-holdings-214300226.html
Dr. Pernichery Narayan announced as new Caverstem Doctor - https://finance.yahoo.com/news/shareholder-creative-medical-technology-holdings-214300226.html
August 16 - 8K, recap of PR released on 8/14 - http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=12417002&type=HTML&symbol=CELZ&companyName=Creative+Medical+Technology+Holdings+Inc&formType=8-K&dateFiled=2018-08-16
August 17 - Caverstem Switzerland video ad released -
August 24 - Caverstem announces booth information for Regional AUA Conference on Sep 6-7 in Chicago - https://www.facebook.com/pg/caverstem/posts/
Dr. Peter Niemczyk is announced as a Caverstem provider for Phoenix area - https://www.facebook.com/1917580464922513/posts/259611531706902
Two new location domains registered
August 27 - One new location domain registered
August 29 - One new location domain registered
August 30 - www.caverstem-florida.com website became active
Aug 31 - Two new Caverstem ad videos released(including one international) -
Sep 4 - PR released on Caverstem domestic/international progress, clinical trial update, AUA Regional Conference, female sexual dysfunction treatment, hiring new salesperson focusing on East Coast- https://www.prnewswire.com/news-releases/shareholder-update-creative-medical-technology-holdings-inc-300706149.html
www.caverstem-phoenix.com website becomes active - https://t.co/vMMCnpV3EQ
Sep 6-7 - Caverstem attending Regional AUA Conference in booth 313
Sep 10 - New Caverstem ads/videos including German video -
Sep 18 - Los Angeles website for Dr. Gershman becomes active - https://twitter.com/JBizzle703/status/1042198947920523264
Sep 21 - Caverstem.com “Find a Doctor” page gets populated with their domestic providers - https://twitter.com/JBizzle703/status/1043265358830989313
Sep 24 - PR release covering multiple topics: Institutional investors to provide working capital moving forward; Caverstem Russia to begin treatments in Oct; Caverstem Switzerland providing treatment soon; successful AUA Chicago Conference with new leads; training and on boarding of providers with contracts continues; will be attending Sexual Medicine Society of North America conference in November; will begin to unveil FemCelz(for female sexual dysfunction) shortly. https://www.prnewswire.com/news-releases/shareholder-update-creative-medical-technology-holdings-inc-300717453.html
Caverstem.com Update
Nice update to the @CaverStem webpage, where they have updated the "Find a Doctor" page and are now listing providers.
http://www.caverstem.com/find-a-doctor-2/
@MdFacep @GershmanMDLA @Freedmanurology @CSUF_Phoenix @SDUrology @VictorLiuMDFACS
#urology #stemcells #erectiledyfunction
New @CaverStem domain active, #LosAngeles
http://www.caverstem-losangeles.com/dr-alex-gershman/ … …
I would assume this is a pre-emptive move, and will result in the 'Find A Doctor' page on the main site, serving more as a complete list of Caverstem providers, instead of showing Dr. Gershman's info.
$CELZ
I remember that, wasn't it quite a bit too like 1M+?
That's just the registered agent's address, the other address associated with it is 3008 W LUPINE AVE, PHX. This I believe is Mr. Warbington's address. They have used it recently for other filings and other types of registrations(web domains).
Physician Contacts
I have contacted many of the physicians listed as well over the past month or two.
Dr. Bieri said he and Dr. Said would begin treatment in mid Sept-Oct as they were having a new office space created.
Dr. Liu's office manager stated they were providing the treatment.
Dr. Brown's office manager stated they would be providing treatment by end of August.
Dr. Bachmann(Switzerland) responded that they would be providing treatment by mid fall.
I also physically visited Dr. Freedman's office in Las Vegas and they were aware of Caverstem but had not been yet set up for training(this was beginning of August).
No one needs to believe any of this though, as they can easily verify the information by doing the same thing I did, which is get their offices email addresses(off of their Caverstem page or from the doctor's home pages which are linked from their Caverstem page).
Likewise, if you were to actually contact Caverstem as a potential patient, they will call you back and provide you with information on doctors closest to you.
Go Pats! Maybe one day, there will be a Caverstem Suite there, lol.
Quote BS LOL "3 ba ba BILLION SHARES AVAILABLE TO ISSUE...they had to...because of the set-asides required for ALL THE TOXIC CONVERTIBLE FLOORLESS NOTES THEY'RE INKING TO STAVE OFF BK"
Uh....NO....FALSE....TOTAL BS TO ME.......
They did not raise the A/S to 3 Billion over this past weekend or any time recently. Anyone who has been following this stock knows that the A/S has been set at this number since the earlier part of this year. So saying they are raising the A/S for any reason is a blatant misrepresentation.
Section F-2
http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=12159314&type=HTML&symbol=CELZ&companyName=Creative+Medical+Technology+Holdings+Inc&formType=10-K&dateFiled=2018-03-29
Updated DD list since AUA Conference with links to source
May 20 - Introducing Caverstem at AUA Conference in San Francisco - http://www.caverstem.com/creative-medical-technology-holdings-inc-to-unveil-its-patented-caverstem-procedure-for-erectile-dysfunction-at-international-urology-conference/
May 21 - 10-Q published - http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=12269334&type=HTML&symbol=CELZ&companyName=Creative+Medical+Technology+Holdings+Inc&formType=10-Q&dateFiled=2018-05-21
May 22 - Social media campaign begins(Hired someone for outreach and Dr. Gershman’s social media accounts created) -
Alexander Gershman, M.D. is a Board-Certified Urologist & is considered to be one of the world’s leading Urology experts in the area of minimally invasive surgery. https://t.co/AzauL896wZ #urology #ErectileDysfunction #caverstem #ed #beverlyhills #maleenhancement pic.twitter.com/HGdTrTLcOT
— Institute for Advanced Urology (@GershmanMDLA) May 22, 2018
Dr. Alexander Gershman performing the first part of the #CaverStem Procedure which is Bone Aspiration. #StemCells #ErectileDysfunction #LosAngeles pic.twitter.com/yYznwViH5L
— Institute for Advanced Urology (@GershmanMDLA) June 18, 2018
CaverStem International - Switzerland pic.twitter.com/lA61DjBmHS
— CaverStem (@CaverStem) August 18, 2018
AS has been 3B since I started following in Feb.
If I wasn't, I don't know whose team I would be on. Not like I would spend my time posting on a board for a stock I didn't like, using bold fonts and scary colors.
New Caverstem Commercial
New @Caverstem #Switzerland commercial:
Nice catch!
Damn man! You broke that before I did, lol. I was just starting to go through the total list to look for new active domains. And didn't even think the new domain name would be the active one.
The already have a boat load of FL domains, so I assume that will keep growing. And with LA, really there are so many parts of it, they will break it down into various domains, like they did with the WEHO(West Hollywood) this past weekend.
New Caverstem Location Domains
Two new @Caverstem location domains added during the week(Monday and Wednesday):
www.caverstem-florida.com
www.caverstem-losangeles.com
@CelzFans @AmerUrological @Uroweb
#urology #stemcells #erectiledysfunction #menshealth
Nice to see that Dr. Gershman was over in Europe!
Two new location domains registered
Two new location domains added last Friday:
www.caverstem-sf.com
www.caverstem-weho.com
#urology #stemcells #erectiledysfunction #menshealth @CaverStem @AmerUrological
Potential Treatment Rollouts
Depends on the doctor, but I would caution about getting excited about them providing the anti-aging treatments right now, they have not yet gone through any type of FDA approval for that. From my perspective their treatment path should follow as such:
1. Caverstem (already in commercialization, FDA approval not needed due to the mesenchymal stem cells derived from bone marrow, see CFR Title 21 FDA chapter I, Subchapter L).
2. Either StemSpine or AmmnioStem for Cachexia treatment
2a. StemSpine is in the same FDA approval situation as Caverstem, it in essence the same process just injected into a different part of the patients body. They have not done a clinical trial on it, like they did with Caverstem. So, there's nothing stopping them from doing it right now, but would perhaps want more data to back it up.
2b. Amniostem treatment for cachexia would get to be fast tracked due to the Right to Try law. That means, it would hypothetically only need to go through FDA Type 1 clinical trials, which can be done in a few months period.
3. All other Amniostem treatments(anti-aging, stroke therapy, cerebrostem, sexual dysfunction, etc.) would I believe need to go through some other type of more vigorous testing.
I was going to give you the number to the Caverstem customer service rep. Of course, you can get that same number if you go to www.caverstem.com and fill out their "Initial Consultation" form, because they will contact you pretty quickly.
As far as I know there are no active doctors on the east coast, the Florida doctor, Dr. Perinchery Narayan, MD at North Florida Urology with offices in Orlando, Ocala, Gainsville, St. Augustine and Palatka, FL is going to be the only person I know of at the moment who has been announced, but I don't have a date of when he will start(I would assume very shortly, based on me reaching out to the other doctors that they have announced).
https://www.vitals.com/doctors/Dr_Perinchery_Narayan.html
Are you on Twitter, if you are shoot me a DM.
Updated DD list since AUA Conference with links to source
May 20 - Introducing Caverstem at AUA Conference in San Francisco - http://www.caverstem.com/creative-medical-technology-holdings-inc-to-unveil-its-patented-caverstem-procedure-for-erectile-dysfunction-at-international-urology-conference/
May 21 - 10-Q published - http://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=12269334&type=HTML&symbol=CELZ&companyName=Creative+Medical+Technology+Holdings+Inc&formType=10-Q&dateFiled=2018-05-21
May 22 - Social media campaign begins(Hired someone for outreach and Dr. Gershman’s social media accounts created) -
Alexander Gershman, M.D. is a Board-Certified Urologist & is considered to be one of the world’s leading Urology experts in the area of minimally invasive surgery. https://t.co/AzauL896wZ #urology #ErectileDysfunction #caverstem #ed #beverlyhills #maleenhancement pic.twitter.com/HGdTrTLcOT
— Institute for Advanced Urology (@GershmanMDLA) May 22, 2018
Dr. Alexander Gershman performing the first part of the #CaverStem Procedure which is Bone Aspiration. #StemCells #ErectileDysfunction #LosAngeles pic.twitter.com/yYznwViH5L
— Institute for Advanced Urology (@GershmanMDLA) June 18, 2018
CaverStem International - Switzerland pic.twitter.com/lA61DjBmHS
— CaverStem (@CaverStem) August 18, 2018
New Caverstem Doctor
New @CaverStem provider, Dr. Niemczyk from the Phoenix area.
https://www.facebook.com/1917580464922513/posts/2596115317069021/ …
#urology #stemcells #erectiledysfunction
AUA North Central Regional Conference
@CaverStem #AUA18 North Central Region Conference, September 6-7, booth 313.
#urology #erectiledysfunction #stemcells @AmerUrological @Uroweb $celz
Cachexia Patent is also applicable to HIV treatment
Reading CELZ patent on treating #cachexia with #Amniostem. This patent is also applicable to #HIV related wasting!
http://www.freepatentsonline.com/y2018/0133258.html
https://www.jwatch.org/ac199611010000001/1996/11/01/hiv-wasting-syndrome
#oncology #cancer #pinkribbon #wastingsyndrome #InternalMedicine #health
Updated CELZ Patents:
ED Patent. CMH acquired the use patent application for treatment of ED by stem cell therapy in July 2011 and prosecuted the application until the ED patent was issued in 2013. We have closed a Patent Purchase Agreement dated February 2, 2016, with CMH to acquire the ED patent and related know-how and technology for 64,666,667 shares of our common stock. The assignment documents have been filed with the U.S. Patent and Trademark Office.
Lower Back Pain Patent. StemSpine, LLC acquired U.S. Patent No. 9,598,673 covering use of various stem cells for treatment of lower back pain (the “ Patent ”). The inventors of the Patent were Thomas Ichim, PhD and Amit Patel, MD, each a director of the Company, CMT, and CMH, and Annette Marleau, PhD, a Vice-President of the Company. The managers of StemSpine are Timothy Warbington, Donald Dickerson, and CMH. The Patent was issued on March 21, 2017.
Immune System Cells for Stimulation of Perispinal Angiogenesis Application. The two patent applications, No. 62520773 and No. 62513670, filed on June 16, 2017 and June 1,, 2017, respectively, cover the novel use of cells, conventionally known as immune system cells, to stimulate formation of new blood vessels, a process termed angiogenesis. Several studies support the notion that patients suffering from lower back pain exhibit a reduction in blood flow to the lower back area. The Company has data supporting the use of immune cells from both the innate and adaptive arms of the immune system for stimulation of new blood vessel formation, which is believed to be beneficial for overcoming circulation defects in patients with lower back pain
Multipotent Amniotic Fetal Stem Cells License Agreement. On August 25, 2016, CMT entered into a License Agreement dated August 25, 2016, with The Regents of The University of California, represented by its San Diego campus of the University of California, San Diego, Office of Innovation and Commercialization. This license agreement grants to CMT the exclusive right to all products derived from U.S. Patent No. 7,569,385 for use of multipotent amniotic fetal stem cells composition of matter throughout the world during the period ending on the expiration date of the longest-lived patent rights under the patent. The license agreement also permits CMT to grant sublicenses. Under the terms of the license agreement, CMT is required to diligently develop, manufacture, and sell any products licensed under the agreement. We are required to pay the University an initial license fee within 30 days of entering into the agreement. We are also required to pay annual license maintenance fees on each anniversary date of the agreement, which maintenance fees would be credited toward any earned royalties for any given period. The License Agreement provides for payment of various milestone payments, which in the aggregate are estimated at approximately $2,000,000, and earned royalties on the net sales of licensed products by CMT or any sublicensee of between approximately 5% and 20%. CMT is also required to reimburse the University for any future costs associated with maintaining the patent. CMT may terminate the license agreement for any reason upon 90 days’ written notice and the University may terminate the agreement in the event CMT fails to meet its obligations set forth therein, unless the breach is cured within 30 days of the notice from the University specifying the breach. CMT is also obligated to indemnify the University against claims arising due to the exercise of the license by CMT or any sublicensee. CMT is also required to maintain adequate general liability insurance.
Multipotent Amniotic Fetal Stem Cells for Stroke Therapy Application. On Dec. 13, 2016 CMT filed US patent application #62/400557 entitled “Treatment of Stroke by Amniotic Fluid Derived Stem Cell Conditioned Media and Products Derived Thereof.”. The patent application covers the use of the Company’s newly licensed AmnioStem stem cell as a production means for generation of nanoparticles termed “exosomes,” which regenerate damaged brain tissue after stroke.
Multipotent Amniotic Fetal Stem Cells for Radiation Toxicity Application. On April 4 2017 CMT filed a US patent application covering the use of its AmnioStem Universal Donor stem cell product as a treatment of radiation toxicity. We plan to leverage the ability of its amniotic fluid based stem cell product to induce a process termed “neurogenesis” in which specific areas of the brain are activated to repair damaged tissue.
AmnioStem™ Mediated Immune Reprogramming for Stroke Application. On May 24, 2017 CMT filed a US patent application covering a novel means of suppressing inflammation associated with stroke by reprogramming immune cells of the stroke victim. The patent application teaches ways of using the Company’s patented AmnioStem™ allogeneic stem cell to ‘educate’ immune cells from stroke patients so as to reduce inflammation associated with stroke. By reducing inflammation, the Company plans to develop novel means of increasing efficacy of therapeutic agents in stroke patients.
Synergy between intradiscal stem cell injection subsequent to stimulation of perispinal angiogenesis. On June 7, 2017 we filed a US patent application covering synergy between intradiscal stem cell injection subsequent to stimulation of perispinal angiogenesis. This patent expands on the Company’s issued US Patent #9,598,673, which covers treatment of lower back pain by injection of stem cells into muscles surrounding the lower back to stimulate new blood vessel formation (angiogenesis). Nutrition of the avascular intervertebral disc occurs by diffusion through the vertebral endplates from the blood vessels in the vertebral bodies above and below the disc. In many patients with lower back pain, cholesterol plaques in the wall of the aorta obliterate orifices of lumbar and middle sacral arteries and decrease blood supply of the lumbar spine and its surrounding structures. As a result, structures with precarious nutrient supply, such as the intervertebral discs, gradually degenerate. We plan to employ the new technology to modify the environment in the disc, so as to give the injected stem cells optimal conditions for regeneration
Immune Modulatory Cells for Stimulation of Perispinal Angiogenesis to Induce Regeneration of Degenerated Discs. On June 24, 2017 we announced the filing of intellectual property covering data supporting the use of immune system cells for stimulation of perispinal angiogenesis as a means of treating patients with lower back pain, as well as supporting intradiscal stem cell administration in patients suffering from degenerative disc disease. The two patent applications, No. 62520773 and No. 62513670, filed on June 16th and June 1st, respectively, cover the novel use of cells, conventionally known as immune system cells, to stimulate formation of new blood vessels, a process termed angiogenesis.
Autologous Bone Marrow Mononuclear Cells as a Substrate for Enhancement of Neuroregenerative Therapy Application. On October 11, 2017 CMT filed a US patent application covering the use of a combination of an FDA approved drug together with the patient’s own bone marrow derived stem cells for the treatment of stroke. The patent covers the use of the patient’s bone marrow stem cells, together with an FDA approved drug, to stimulate the naturally occurring regenerative processes after certain types of strokes. We plan to we augment the naturally occurring approach by extracting stem cells from the bone marrow, placing them in circulation, and administering an FDA approved drug to enhance their activity
Male Infertility License Agreement. Effective January 29, 2016, we entered into a License Agreement with LABIOMED granting us an exclusive license in the U.S. and its territories and possessions to make and market products or services authorized under LABIOMED’s U.S. use Patent Application 14/508,763 (filed October 7, 2014, and claiming priority back to U.S. Ser. No. 60/790,085 filed on 4/7/2006). We also have the right, with LABIOMED’s consent, to grant sublicenses. Subject to early termination provisions, the license agreement expires on the last to expire of the patents under which the license was granted. We have the right to terminate the agreement at any time upon 90 days’ prior written notice. LABIOMED has the right to terminate the agreement upon the breach of certain covenants under the agreement, including the failure to make required payments to LABIOMED, failure to obtain and maintain required insurance coverage, our failure to meet performance milestones, our insolvency or bankruptcy, underreporting or underpayment of royalties in excess of 20% for any 12-month period, our challenge to the patent rights underlying the license, or our default in the performance of any obligations under the agreement not cured within 90 days following receipt of notice. The agreement obligates us to use our commercially reasonable efforts to develop and commercialize the licensed products and to initiate human clinical trials within specified times. If we fail to meet these milestones within the designated periods, LABIOMED may terminate the license or convert it to non- exclusive. Under the terms of the agreement we paid $5,000 to LABIOMED as a non-refundable license issue royalty, agreed to reimburse them up to $1,800 for its expenses in reviving the patent application, and issued 323,333 shares of CMT’s common stock. We are subject to a 6% royalty to LABIOMED on net sales of any licensed products and 25% on any non-royalty sublicense income. Commencing three years after the date of the agreement, and each subsequent year thereafter, we are required to pay annual maintenance royalties of $20,000, unless during the prior one-year period we paid $50,000 or more in actual royalty payments. Finally, we have agreed to pay them certain milestone payments upon achieving the milestones set forth in the agreement, which in the aggregate we estimate to be approximately $300,000.
Female Sexual Dysfunction Patent Application. Drs. Patel and Ichim, two of our directors, have assigned to CMT for nominal consideration use their patent application (U.S. Patent Application 62319753) for the use of regenerative cells as a treatment option for women who experience sexual desire, but have difficulty reaching the arousal stage. The patent application was filed with the U.S. Patent and Trademark Office on April 7, 2016. This patent was assigned to CMT on August 28, 2016.
Miscarriage Treatment Patent Application. CMT scientists Drs. Patel and Ichim have also assigned to CMT for nominal consideration their U.S. use Patent entitled “ Adipose Derived Immunomodulatory Cells for Immunotherapy of Recurrent Spontaneous Abortions ”, (U.S. Patent Application 62/347,898) which covers the use of a woman’s own fat derived stem cells for prevention of pregnancy loss. The patent application was filed with the U.S. Patent and Trademark Office on June 9, 2016. This patent was assigned to CMT on August 28, 2016.
Treatment of Cachexia Using Stem Cells and Products Thereof. Recently the Company announced data that the AmnioStem™ stem cell was superior to other stem cell types at reducing inflammatory mediators, including TNF-alpha1. It is well known that inflammatory mediators generated by cancer have a pivotal contribution to cancer associated weight loss, formally termed "cachexia". The Company believes that through suppression of inflammatory mediators, as well as direct anticancer effect of amniotic fluid stem cells2,3that AmnioStemTM may provide value in the treatment of advanced cancer patients. This will be done through the in-licensing of patent application #15/814284 entitled "Treatment of Cachexia Using Stem Cells and Products Thereof".
100% agree!
I would think that is better. I can't speak for anyone by myself. It's just another positive data point for me. I think we all can come up with possible reasons for lack of increase in volume and PPS. For me personally(I know this doesn't apply to everyone). I really don't care what it does tomorrow or next week, or even next month. I'm holding it at least 12 months. Seeing what they have done over the past 6 months(both from a PPS/market cap and quantifiable action perspective) has been impressive and leads me to believe they will continue along that path.
Don't forget France too(domain for France/Paris).
That was my understanding. Christine Schroder, who works for ISTO Biologics, which makes the Magellan device. She is the lady that is interviewing Dr. Gershman in the AUA and follow up videos. She is also the lady that is seen in the youtube video training Dr. Gershman's nurse. That's all I've been able to piece together just from watching those videos. I don't know what other folks they have who might also be doing training.
$CELZ #AmnioStem DD
Some of the evidence for the AmnioStem treatment for #Cachexia, @NIH article "Human amniotic fluid derived mesenchymal stem cells cause an anti-cancer effect on breast cancer cell line in vitro".
https://www.ncbi.nlm.nih.gov/pubmed/27262812
#oncology #cancer #pinkribbon
That is a very good point!
Caverstem Swizterland
Looks like the next @CaverStem webpage to become active is the #Switzerland one. It now has the default WordPress page up, meaning someone is starting to work on it. Will be $CELZ first international page. I wonder if they are offering treatment soon?
http://www.caverstem-switzerland.com
Couldn't have said it better myself.
I wouldn't expect that the results will be end of the month. Twelve months after the final patient signed up for the trial will be the 18th of August. I assume the majority of the data has already been collected and they have been formalizing the results, but it should be peer reviewed. They could start to release data after that point, but I would be expecting the full report this month.
Since they've actually already had most of the data from most of the clinical trial patients, the data would obviously have had to be pretty good for them to continue forward with commercialization.
http://www.firstwordpharma.com/node/1500332?tsid=17
Hey Fly, shoot me a DM on twitter.